Evidence analysisNovember 14, 2026Evidence
EMEA-000898-PIP01-10-M02

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Evidence Dossier: Paediatric Investigation Plan for Meropenem (EMEA-000898-PIP01-10-M02)
What is Established
Meropenem is a broad-spectrum antibiotic used in the treatment of serious bacterial infections, including bacterial meningitis and sepsis, administered intravenously. The European Medicines Agency (EMA) oversees the regulation and approval of paediatric investigation plans (PIPs), which are designed to ensure medicines are appropriately studied in children. Each PIP outlines the strategy for paediatric studies to support authorised use of a medicine in children.
The EMA document referenced (Decision P/0065/2016) relates to an agreed modification of a paediatric investigation plan for meropenem, indicating the drug’s ongoing development and evaluation for use in children with serious infections. The plan concerns meropenem formulated as a powder for solution for injection or infusion. The modification decision was adopted on 18 March 2016 and relates to a plan initially agreed under the PIP number EMEA-000898-PIP01-10-M02.
In addition, a notification dated 13 November 2026 mentions the discontinuation of a paediatric development programme covered by this agreed PIP, signaling shifts in the development pathway.
What the Source Claims
- The paediatric investigation plan for meropenem has undergone changes formally accepted by the EMA.
- The planned studies target serious infections in children, specifically bacterial meningitis and bacterial sepsis, conditions that require precise dosing and safety data for paediatric populations.
- The drug is administered intravenously, which necessitates careful clinical protocols for administration in children.
- Contact for the PIP is managed by the NeoMero Consortium in Italy, suggesting a collaborative research or development effort focused on meropenem’s paediatric use.
- The source includes an official notification related to the discontinuation of a segment of the paediatric development programme covered by this PIP, implying changes or challenges in the clinical development process.
What May Be Missing from the Usual Framing
The EMA documentation is regulatory and technical in nature, focused on compliance and procedural decisions rather than clinical outcomes or detailed development challenges. It lacks publicly available information on:
- The scientific rationale for the modification of the PIP or the specific nature of changes made in 2016.
- The reasons for the paediatric development discontinuation noted in 2026, such as safety concerns, efficacy issues, commercial decisions, or logistical difficulties.
- Data on actual trial results, patient outcomes, or data relating to dosing, efficacy, and safety in the paediatric population.
- Potential alternative therapies or clinical approaches for paediatric bacterial meningitis and sepsis in context with meropenem’s development changes.
Competing Evidence or Uncertainty
The primary source is an official regulatory document, which assures the accuracy of information on decision processes and PIP status. However:
- No publicly accessible clinical trial data or peer-reviewed publications linked to this PIP are included.
- The reasons for modification and discontinuation are not detailed, leaving uncertainty as to whether these reflect scientific, clinical, commercial, or logistical considerations.
- Without clinical data transparency, it is unclear how meropenem performed in paediatric investigations, or what evidence supports or challenges its use for meningitis and sepsis in children.
- Other regulatory bodies or independent clinical research may provide additional information, but such evidence is not referenced in the EMA source.
Why It Matters
Serious bacterial infections like meningitis and sepsis in children require effective, safe antibiotics with dosing regimens tailored to paediatric physiology. Regulatory oversight via PIPs aims to ensure that medicines like meropenem receive appropriate evaluation, avoiding extrapolation solely from adult data.
Understanding modifications and discontinuations in paediatric development pathways highlights challenges in drug development for children, a group historically underserved in clinical research. These developments can impact the availability of effective treatment options for vulnerable populations and inform healthcare decision-making.
Transparency and clarity about clinical data and development decisions are critical for clinicians, parents, and policymakers to assess the benefits and risks of paediatric therapies.
What to Verify Next
- Detailed clinical trial results concerning meropenem’s safety and efficacy in paediatric patients for bacterial meningitis and sepsis.
- Clarifications or official statements explaining the rationale behind the PIP modification in 2016 and the paediatric development discontinuation in 2026.
- Information from other regulatory agencies or independent research groups on meropenem’s paediatric use.
- Alternative treatment protocols or medicines being evaluated for these serious bacterial infections in children.
- Broader context about the NeoMero Consortium’s role and activities related to paediatric antibiotic development.
- Check the original EMA source directly to confirm the regulatory context and any updates post-2026.
Readers are advised to consult the original European Medicines Agency documentation for the most accurate and up-to-date information on this paediatric investigation plan.
Source & verification
Primary source: What's new · November 13, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…